Who owns EUPRAXIA PHARMACEUTICALS INC?
- Ticker: EPRX
- CUSIP Number: 29842p105
Tip: Access positions for across all investors
Analyze quarterly positions in Eupraxia Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Eupraxia Pharmaceuticals stock
Who bought or sold EUPRAXIA PHARMACEUTICALS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Beutel, Goodman & Company | 3.7M | $28M | -9% | Dec 2025 |
|
| Vivo Capital | 1.4M | $10M | 0% | Dec 2025 |
|
| Balyasny Asset Management | 1.4M | $10M | 0% | Dec 2025 |
|
| Scotia Capital | 1.3M | $7.2M | 4% | Mar 2026 |
|
| Dr. Jeffrey R. Jay, M.D. | 1.2M | $9.1M | 0% | Dec 2025 |
|
| UBS Group | 763k | $5.5M | 247% | Mar 2026 |
|
| Point72 Asset Management | 712k | $5.4M | 100% | Dec 2025 |
|
| Ikarian Capital | 610k | $4.6M | 100% | Dec 2025 |
|
| Ally Bridge Group | 398k | $3.0M | -57% | Dec 2025 |
|
| Velan Capital Investment Management | 352k | $2.7M | 0% | Dec 2025 |
|
| Aisling Capital Management | 325k | $2.4M | 100% | Mar 2026 |
|
| Affinity Asset Advisors | 300k | $2.3M | 0% | Dec 2025 |
|
| Arrowstreet Capital, Limited Partnership | 278k | $2.1M | 100% | Dec 2025 |
|
| SummitTX Capital | 176k | $1.3M | 100% | Dec 2025 |
|
| Marshall Wace | 158k | $1.2M | 100% | Dec 2025 |
|
| Boothbay Fund Management | 156k | $1.2M | 100% | Dec 2025 |
|
| CIBC World Markets | 151k | $1.1M | 160% | Mar 2026 |
|
| Acadian Asset Management | 94k | $671k | -40% | Mar 2026 |
|
| Hudson Bay Capital Management | 92k | $669k | 100% | Mar 2026 |
|
| TD Waterhouse Canada | 82k | $590k | 751% | Mar 2026 |
|
| Ingalls & Snyder | 76k | $548k | -2% | Mar 2026 |
|
| Goldman Sachs Group | 58k | $438k | 45% | Dec 2025 |
|
| Raymond James Financial | 53k | $400k | 59% | Dec 2025 |
|
| Quadrature Capital | 43k | $326k | 100% | Dec 2025 |
|
| Bank Of Montreal | 38k | $276k | 100% | Mar 2026 |
|
| Persistent Asset Partners | 38k | $275k | 100% | Mar 2026 |
|
| Jane Street | 35k | $254k | 19% | Mar 2026 |
|
| Goodman & Company, Investment Counsel | 32k | $243k | 100% | Dec 2025 |
|
| XTX Topco | 16k | $122k | 100% | Dec 2025 |
|
| Axq Capital | 16k | $114k | 100% | Mar 2026 |
|
| Geode Capital Management | 14k | $105k | 100% | Dec 2025 |
|
| TCI Wealth Advisors | 11k | $80k | 0% | Mar 2026 |
|
| Aptus Capital Advisors | 11k | $76k | 5% | Mar 2026 |
|
| China Universal Asset Management | 10k | $72k | 100% | Mar 2026 |
|
| Guardian Wealth Advisors, Llc / Nc | 10k | $76k | 100% | Dec 2025 |
|
| Federation des caisses Desjardins du Quebec | 9.1k | $49k | 0% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 6.4k | $47k | 100% | Mar 2026 |
|
| National Bank Of Canada /fi/ | 586.00 | $4.4k | -34% | Dec 2025 |
|
| Caitong International Asset Management | 1.00 | $7.000000 | 100% | Mar 2026 |
|
Who sold out of Eupraxia Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Logos Global Management | Sep 2025 | 900k | $5.3M |
| Alyeska Investment Group | Sep 2025 | 250k | $1.5M |
| Guardian Partners | Sep 2025 | 24k | $147k |
| Jpmorgan Chase & Co | Sep 2025 | 17k | $97k |
| Integrated Wealth Concepts | Sep 2025 | 12k | $71k |
| Tower Research Capital | Sep 2025 | 9.00 | $53.000100 |